Ehlken Birgit, Ihorst Gabriele, Lippert Barbara, Rohwedder Angela, Petersen Gudula, Schumacher Martin, Forster Johannes
MERG, Medical Economics Research Group, Munich, Germany.
Eur J Pediatr. 2005 Oct;164(10):607-15. doi: 10.1007/s00431-005-1705-0. Epub 2005 Jun 18.
Data on the economic burden of lower respiratory tract infections (LRTI) in young children are lacking in Germany. The objective of the cost-of-illness study was to estimate the economic impact of community-acquired LRTI and nosocomial LRTI as well as of infections due to respiratory syncytial virus (RSV), parainfluenza viruses (PIV) and influenza viruses (IV). The economic analysis is part of the PRIDE study, a prospective, multi-centre, population-based epidemiological study on the impact of LRTI in children aged 0 to 36 months in Germany. The analysis includes children with community-acquired infections (1329 cases treated as outpatients, 2039 cases treated as inpatients) and nosocomial infections (90 cases). Medical services consumed were generated by chart abstraction and parental expenses data by telephone interviews within four weeks after physician visit or hospitalisation. Costs were evaluated from following perspectives: third party payer, parent and society. Total costs for outpatient treatment are Euro 123 per LRTI case. Stratified by virus type, total costs per case are Euro 163 (RSV), Euro 100 (PIV) and Euro 223 (IV). Total costs per hospitalised LRTI case amount to Euro 2579. Stratified by virus type, total costs per case are Euro 2772 (RSV), Euro 2374 (PIV) and Euro 2597 (IV). Total costs per nosocomial case are Euro 2814. Economic burden due to LRTI is Euro 213 million annually. It is concluded that treatment of LRTI in children up to age three causes a considerable economic burden in Germany. Presented results are the first data describing the economic burden of LRTI in young children assessed by means of the incidence data for Germany. This cost-of-illness study provides basic data for further decision-making, focusing on the economic assessment of preventive strategies for RSV, PIV and IV infections.
德国缺乏关于幼儿下呼吸道感染（LRTI）经济负担的数据。本疾病成本研究的目的是估计社区获得性LRTI和医院获得性LRTI以及呼吸道合胞病毒（RSV）、副流感病毒（PIV）和流感病毒（IV）所致感染的经济影响。该经济分析是PRIDE研究的一部分，PRIDE研究是一项针对德国0至36个月儿童LRTI影响的前瞻性、多中心、基于人群的流行病学研究。分析包括社区获得性感染儿童（1329例门诊治疗病例，2039例住院治疗病例）和医院获得性感染儿童（90例）。所消耗的医疗服务通过病历摘要获取，家长费用数据通过在医生就诊或住院后四周内进行电话访谈获得。从第三方支付者、家长和社会等角度评估成本。每例LRTI门诊治疗的总成本为123欧元。按病毒类型分层，每例的总成本分别为163欧元（RSV）、100欧元（PIV）和223欧元（IV）。每例LRTI住院病例的总成本为2579欧元。按病毒类型分层，每例的总成本分别为2772欧元（RSV）、2374欧元（PIV）和2597欧元（IV）。每例医院获得性感染病例的总成本为2814欧元。LRTI每年造成的经济负担为2.13亿欧元。得出的结论是，在德国，三岁以下儿童的LRTI治疗造成了相当大的经济负担。所呈现的结果是通过德国发病率数据评估得出的关于幼儿LRTI经济负担的首批数据。本疾病成本研究为进一步决策提供了基础数据，重点是对RSV、PIV和IV感染预防策略的经济评估。
